Trinity commits $20 million to ABM Respiratory Care
The financing supports commercial expansion and respiratory care technology. Lenders still need to establish who owes the manufacturer and when payment is due.
Trinity Capital committed $20 million in growth capital to ABM Respiratory Care on October 20. The medical technology company plans to use the financing to expand commercial sales and support product development, clinical research and connected respiratory care. Trinity’s announcement describes a commitment, without stating how much ABM has drawn. For lenders financing medical-device businesses, the collection file needs to identify who buys the equipment and who owes the manufacturer. A device used in a hospital or a patient’s home can pass through different purchasing arrangements. Clinical adoption alone cannot establish when the manufacturer will receive cash. Brokers should resolve that payment path before using a growth announcement to support another financing request. In its separate announcement , ABM said its BiWaze platform includes two FDA-cleared respiratory therapy systems. BiWaze Clear delivers oscillating lung expansion therapy to help mobilize secretions and clear the lower airways. BiWaze Cough helps patients with an ineffective cough clear secretions. The company says both systems are designed for hospital and home care settings. ABM also described Arc Connect, its digital health platform for patient engagement, therapy tracking and care-team visibility into treatment use. The FDA-clearance statement applies to the two BiWaze systems. The release does not extend that statement to Arc Connect. Nor does the announcement provide evidence that therapy tracking has improved collections or reduced credit losses. The two financing releases disclose no interest rate, maturity, repayment schedule or collateral package. Neither gives a revenue figure or a receivables aging schedule. Those limits prevent an assessment of debt-service capacity from the announcement alone. They also leave the amount and timing of any remaining funding availability unclear. A broker should obtain the signed facility terms and current draw information before describing the full commitment as cash available to spend. ABM’s own reimbursement resources page directs questions about billing, coverage and payer documentation to a provider representative or reimbursement consultant. That identifies a separate set of payment questions from device clearance. It does not establish coverage for every patient, a fixed reimbursement amount or a payer guarantee. The financing releases do not explain how reimbursement affects ABM’s customer contracts. A useful credit review would start with the sales contract and invoice. If a distributor buys the device, the manufacturer’s immediate exposure may be to that distributor rather than to the patient’s insurer. If another customer buys directly, the reviewer needs that customer’s acceptance and payment terms. These are questions to resolve from ABM’s records, not disclosed features of this financing. For a comparable small medical-equipment business, an underwriter should match invoices to deliveries, then trace receipts to the bank account. Credits, returns and disputed invoices need separate treatment. Where an invoice depends on customer acceptance, the file should show that acceptance. Where payment depends on a reimbursement step, the reviewer should identify whose obligation is conditional and what documentation remains outstanding. That review should also separate cash spent on commercial expansion from cash expected from existing sales. Product development and clinical research are among ABM’s stated uses for the financing. Those activities can require spending before they generate receipts. A forecast should therefore show the timing of those costs alongside customer collections and debt payments, rather than assume the commitment will produce an immediate increase in operating cash flow. Opinion Keep treatment data separate from payment evidence A connected device may give a care team useful evidence of treatment use. A lender still needs a named debtor, an enforceable payment obligation and a record of collections. Request those records before treating device activity as support for a larger credit limit. Read more on specialty lending at plutusai.net .